Fulphila (pegfilgrastim-jmdb) Patient Assistance Program
Don’t let the high cost of brand pegfilgrastim biosimilar therapy disrupt your chemotherapy care. We help eligible patients access Fulphila (pegfilgrastim-jmdb) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Fulphila (pegfilgrastim-jmdb) is FDA-approved biosimilar to Neulasta for febrile neutropenia prophylaxis in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy. Once-per-cycle SC injection.
- Without assistance, Fulphila costs commonly run approximately $2,500–$4,000 per dose.
- Through AffordMyPrescriptions, qualifying patients can access Fulphila for a flat $69.95 per month.
- Fulphila is a biosimilar — already a lower-cost alternative to brand Neulasta. Other Neulasta biosimilars: Udenyca, Ziextenzo, Stimufend, Fylnetra. All similar efficacy/safety. Filgrastim (Neupogen with biosimilars Granix, Zarxio, Nivestym, Releuko) — daily injections, also options.
What Is Fulphila Prescription Assistance Program?
Fulphila PAP for oncology patients.
Eligibility, oncology coordination.
AffordMyPrescriptions eliminates that burden. $69.95/month advocacy.
Pharmacy Price Comparison
- Fulphila $2,500–$4,000/dose. Multiple pegfilgrastim biosimilars compete on price:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$3,800/dose | Save substantially |
| CVS Pharmacy | ~$4,000/dose | Save substantially |
| Walmart | ~$2,700/dose | Save substantially |
| Costco | ~$2,600/dose | Save substantially |
Other biosimilars (Udenyca, Ziextenzo, Stimufend, Fylnetra) | Varies | Compete on price |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Fulphila Prescription Program?
Fulphila is itself a biosimilar — already cheaper than brand Neulasta. Multiple pegfilgrastim biosimilars compete; filgrastim biosimilars (daily) also options.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Fulphila:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $2,500–$4,000 per dose per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Emadine assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Fulphila Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Fulphila:
Fulphila is pegfilgrastim biosimilar — pegylated G-CSF. Reduces incidence of febrile neutropenia after myelosuppressive chemotherapy by accelerating neutrophil recovery. Long-acting pegylated form allows once-per-cycle dosing vs daily filgrastim.
How Fulphila Works:
G-CSF (granulocyte colony-stimulating factor) stimulates neutrophil production, maturation, and release from bone marrow. After myelosuppressive chemo, neutrophil count drops (nadir typically 7–14 days post-chemo) — risk of severe infection.
Pegylated G-CSF (pegfilgrastim) has long half-life — single dose ~24 hours after chemo provides sustained neutrophil stimulation through nadir. Reduces febrile neutropenia incidence and hospitalization. Indicated for chemo regimens with febrile neutropenia risk ≥20%.
Form and use:
Fulphila 6 mg SC injection ~24 hours after chemo administration, once per cycle. Available as prefilled syringe or Onpro on-body injector (for Neulasta brand only — not all biosimilars have this delivery option).
Generic availability:
Multiple pegfilgrastim biosimilars: Fulphila, Udenyca, Ziextenzo, Stimufend, Fylnetra. All FDA-approved, similar efficacy/safety. Brand Neulasta. Filgrastim biosimilars (daily injections): Zarxio, Nivestym, Granix, Releuko. Generic filgrastim available.
Warnings:
Splenic rupture (rare), acute respiratory distress syndrome (rare), serious allergic reactions, sickle cell crises (in SCD), glomerulonephritis, leukocytosis (rare blast crisis in MDS/AML if used inappropriately), capillary leak syndrome (rare), thrombocytopenia, aortitis (rare).
FAQ (Frequently Asked Questions)
Costs?
$2,500–$4,000/dose. Already cheaper than brand Neulasta. Other biosimilars compete.
Biosimilar same as brand?
All FDA-approved pegfilgrastim biosimilars (Fulphila, Udenyca, Ziextenzo, Stimufend, Fylnetra) similar efficacy. Insurance often prefers one based on contract.
Different biosimilars same?
All FDA-approved pegfilgrastim biosimilars (Fulphila, Udenyca, Ziextenzo, Stimufend, Fylnetra) similar efficacy. Insurance often prefers one based on contract.
Pegfilgrastim vs filgrastim?
Pegfilgrastim: once per cycle, more convenient. Filgrastim biosimilars: daily injections for several days, often cheaper per dose but more injections
When given?
~24 hours after chemo, once per cycle. Don’t give within 14 days BEFORE next chemo.
Denied?
Different pegfilgrastim biosimilar based on insurance, or filgrastim daily. PAP through manufacturer.
Take Control of Your Medication Costs
Multiple pegfilgrastim biosimilars compete — Fulphila already biosimilar saves vs brand Neulasta. Check eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.